Jagsonpal to acquire 85% stake in Aequitas Healthcare for Rs 20.8 Cr

Listed Co AcquisitionStrategic Transactions View source PDF

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+3.2%1-day move

₹230.11

prior close

₹243.69

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+2.6+6.0+6.7+6.6+3.2+2.1+3.3+3.4+3.9+0.7-3.5———

Up moveDown movePending

AI summary

Jagsonpal Pharmaceuticals will acquire 85% stake in Aequitas Healthcare for Rs 20.8 crore in cash, funded from internal accruals. Aequitas is a Mumbai-based pharma firm focused on hospital sales, with FY26 revenue of Rs 53.31 crore. The deal gives Jagsonpal entry into the hospital channel and institutional doctor network. Not a related party transaction. Expected to close by July 15, 2026.

Likely market impact

Strategic entry into hospital channel. Rs 20.8 Cr cash deal funded internally, no debt impact. Aequitas adds about Rs 53 Cr annual revenue.